Clinical trials: MIS-C Multisystem Inflammatory Syndrome in Children
Multisystem Inflammatory Syndrome in Children (MIS-C)
Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
The aim of this observational study is to assess whether Multisystem Inflammatory Syndrome (MIS-C) in children affects their quality of life.
- Trial name
- MIS-C (NCT07126028)
- Where
- Croatia
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Kristina Lah Tomulić
Covid19, MIS-C Associated With COVID-19
Pediatric COVID Outcomes Study (PECOS)
This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population, including…
- Conditions
- Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
- Trial name
- NCT04830852
- Where
- 2 sites in United States
- Volunteers
- 1,097 people, healthy volunteers welcome
- Sponsor
- Children's National Research Institute
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
Cardiovascular Assessment 5 Years After MIS-C
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system.
- Trial name
- NCT07659847
- Where
- Poland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Multisystem Inflammatory Syndrome in Children (MIS-C)
Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children
Multi-system Inflammatory Syndrome in Children (MIS-C) is a new condition related to COVID-19, the study investigators are still learning about its causes, effects, and long-term impact.
- Trial name
- MUSIC (NCT05287412)
- Where
- 33 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- Carelon Research
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.
- Trial name
- NCT04456439
- Testing
- Remestemcel-L, Hydrocortisone, Diphenhydramine
- Sponsor
- Mesoblast International Sàrl
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Contrast Enhanced Ultrasound in COVID-19
Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion.
- Trial name
- NCT04640038
- Testing
- Sulfur hexafluoride lipid-type A microspheres
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital of Philadelphia
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C)
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
The primary objectives of this study are: To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
- Trial name
- PRISM (NCT04588363)
- Testing
- SARS-CoV-2 and/or MIS-C Exposure
- Where
- 20 sites in United States
- Volunteers
- 244 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
MIS-C Multisystem Inflammatory Syndrome in Children
Immun Response in Children With MIS-C
Multi-system inflammatory syndrome in children (MIS-C) is a post-viral inflammatory vasculopathy of children and adolescents following Covid-19 infection. It affects one of 1000-5000 children.
- Trial name
- NCT05052424
- Testing
- Analysis of cytokines and immun cell related markers
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Cologne